MTOR and urinary bladder carcinoma: In conclusion, we demonstrate the synergistic effect of the combination therapy with AKT (AZD5363) and mTOR (AZD2014 and BEZ235) inhibitors against bladder cancer cells with PI3KCA and mTOR mutations.